NCT00233337已完成4 期
Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 主要终点
- Proportion of patients free of parasites in the blood after 28 days.
研究概览
简要总结
This study will assess the safety and efficacy of co-artemether in the treatment of acute uncomplicated P. falciparum malaria in returning non-immune travellers
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients were eligible for inclusion if they met all of the following criteria:
- •Male or female aged 18 or older (prior to Amendment 1: more than 2 years old)
- •Non-immune patients suffering from acute uncomplicated P. falciparum malaria, or mixed infection including P. falciparum, with parasitemia of less than or equal to 2% asexual P.falciparum parasites, confirmed by microscopy using Giemsa-stained thick film.
- •Non-immune patients were regarded as those who had not spent the first five years of their life, nor the last five years in a malaria endemic area, and did not have acute P. falciparum malaria diagnosed during those past five years.
- •Non-immune patients who had received prophylaxis with anti-malarials (excluding halofantrine) were included only if clear progression of acute P. falciparum infection was documented.
- •Female patients were eligible to participate in the study if they were of non-childbearing potential or had a negative pregnancy test (urine or serum) at screening, and using an acceptable contraceptive method
- •Patients, who had been informed of the study procedures and medication, and had given written informed consent and were willing to comply with the study protocol.
排除标准
- •Patients were to be excluded from participation if they met any of the following criteria:
- •Known hypersensitivity to artemether or lumefantrine
- •Signs/symptoms indicative of severe/complicated malaria according to the WHO classification (e.g. cerebral malaria, see Post-text supplement 1)
- •Treatment with artemisinin derivatives within the previous 7 days
- •Concurrent administration of other treatment / prophylaxis for malaria
- •Concurrent administration of medications with potential hemolytic effects
- •Patients taking any drug metabolized by cytochrome isoenzymes CYP3A4 or CYP2D6
- •Received any other investigational drugs in the last 4 weeks before entry into the study
- •Severe cardiac impairment (i.e. evidence of existing cardiac conduction defect or overt symptoms of cardiac dysfunction or abnormalities of baseline ECG not associated with acute malaria); clinically relevant bradycardia or congestive cardiac failure with reduced left ventricular ejection fraction; pre-existing prolongation of the QT interval; history of symptomatic cardiac arrhythmias
- •Having received halofantrine or any other drug known to influence cardiac function within 4 weeks prior to Screening visit or taking other drugs that are known to prolong the QT interval, including class IA and III antiarrhythmics, neuroleptics, antidepressive agents, certain antibiotics (including some macrolides, fluoroquinolones, imidazole, and triazole antifungal agents), certain non-sedating antihistaminics (terfenadine, astemizole) and cisapride
- •History of splenectomy
- •Clinically significant abnormal baseline hematology (not associated with acute malaria) or clinical chemistry parameters, including evidence of hepatic or renal impairment, known disturbances of electrolyte balance e.g. hypokalemia or hypomagnesaemia
- •Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study, or concomitant disease which could mask the response to treatment
- •Unlikely, in the opinion of the investigator, to complete the dosing or follow-up periods, or who have evidence of alcohol, drug or solvent abuse.
- •Women who are pregnant, lactating or of childbearing potential and not using an acceptable contraceptive method were also excluded.
- •Other protocol inclusion/exclusion criteria may apply
结局指标
主要结局
Proportion of patients free of parasites in the blood after 28 days.
次要结局
- Time to clearance of fever
- Proportion of patients free of parasites in the blood after 7 days
- Time to clearance of parasites in the blood
- Proportion of patients with presence of sexual forms of the parasite in the blood (gametocytes);
- Hematology and biochemistry
研究者
相似试验
已完成
3 期
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.FalciparumMalariaNCT00386763Novartis890
招募中
1 期
Autologous Gene Therapy for Artemis-Deficient SCIDSevere Combined ImmunodeficiencyNCT03538899University of California, San Francisco24
已完成
4 期
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in YaoundeMalaria,FalciparumNCT04565184University of Yaounde 1242
已完成
4 期
Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DMType 2 Diabetes MellitusNCT00612144Handok Inc.192
已完成
2 期
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerBRAF V600E-mutant Metastatic Colorectal CancerNCT03693170Pierre Fabre Medicament95